Clear Search

Showing 2 results for “Tanaka E”.

Risque non accru d'infection avec hospitalisation sous thérapies ciblées versus méthotrexate chez les patients âgés atteints de polyarthrite rhumatoïde : une étude de cohorte rétrospective

Arthritis Res Ther. 2022 doi: 10.1186/s13075-022-02807-9

Retrospective, longitudinal, population-based study shows that despite an overall higher incidence of hospitalised infection (HI) in both elderly and older elderly patients compared to young patients, the risks of HI in patients exposed to targeted therapy versus MTX is not significantly increased.

Lire la Suite…

Arrêt du Tocilizumab après Rémission chez des Patients Atteints de Polyarthrite Rhumatoïde Traités avec du Tocilizumab Seul ou en Association Avec du Méthotrexate: Résultats d'une Étude Prospective Randomisée Contrôlée (deuxième année de l'étude SURPRISE)

Ann Rheum Dis 2018; 77:1268–1275 DOI: 10.1093/rheumatology/key121

The second-year results from the SURPRISE study show that low disease activity (LDA) can be maintained after discontinuation of tocilizumab with continued methotrexate after remission is achieved. Discontinuation of biologic agents in patients who have achieved remission or low disease activity (LDA) is desirable from a risk–benefit point of view. Compared with TNF inhibitors, little is known regarding TCZ-free remission or LDA, but studies indicate that only a small proportion of patients remai...

Lire la Suite…